

AMENDMENTS TO THE CLAIMS:

Please amend claims 1, 7 and 8.

Please cancel claims 9-13, 15, 18-35, and 37-49.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently Amended) An isolated virus-like particle comprising an enveloped virus core said virus-like particle further comprising a heterologous multiple membrane spanning protein.
2. (Previously presented) The virus-like particle of claim 1, wherein said protein is capable of binding with a ligand under conditions wherein said ligand would bind with an otherwise identical protein present on a cell membrane.
- 3-4. (Canceled)
5. (Previously Presented) The isolated virus-like particle of claim 1, wherein said enveloped virus core is derived from a retrovirus.
6. (Previously presented) The isolated virus-like particle of claim 1, wherein said enveloped virus core is selected from the group consisting of a murine leukemia virus, a human immunodeficiency virus, a rabies virus, a Rous sarcoma virus, and a vesicular stomatitis virus.
7. (Currently Amended) The isolated virus-like particle of claim 1, wherein said multiple membrane spanning protein ~~of interest~~ is selected from the group consisting of a G-protein coupled receptor, a transporter protein, and an ion channel protein.
8. (Currently Amended) The isolated virus-like particle of claim 1, wherein said multiple membrane spanning protein ~~of interest~~ is selected from the group consisting of CCR5, CXCR4,

068323-5004-01US
SERIAL NO.: 10/032,311

PATENT
FILED: December 21, 2001

MCAT-1, CXCR2, CXCR3, mu-opoid receptor, and KCNH2 potassium channel protein.

9-50. (canceled)